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and (c) an efﬁcacious and fast process for clinical meaningful interven-
tion (preferably fully automated). The clinical introduction of on-line 
electronic imaging devices (EPID) has led to the improved understand-
ing of treatment uncertainties, and of the need for strategies to further 
reducing them. Already in the early 90ís strategies had been developed 
to use EPID for near real-time patient set-up, and although the ﬁrst 
requirement (3D assessment) could be established by using multiple 
planar images, this procedure never became a mainstream solution as 
it was cumbersome for implementation into the daily workﬂow. Yet, 
this development did raise the awareness of the potential beneﬁts of 
image guidance and the concept IGRT was born. IGRT solutions could 
be classiﬁed as follows: (1) megavolt (MV) imaging, (2) kilovolt (kV) 
imaging, and (3) solutions using non-ionising radiation. Some of these 
IGRT techniques are designed for interfraction target localization, some 
techniques will be able to perform intrafraction target motion manage-
ment. In other words not limited to target observation only, but also 
offering the possibility of controlling the treatment beam based on that 
information for breathing synchronized irradiation. In principle 2 ap-
proaches exist: one uses the image guidance to align the target volume 
with respect to the treatment beam using a robotic couch control system 
in combination with a beam triggering system switching the beam 
on-and-off in synchronization with a breathing signal, the other in 
turn, uses the imaging information to guide the treatment beam using 
a robotic linac or computer control of the beam collimating system to 
actually follow the target during beam-on. The latter has the potential 
of true real-time tumor tracking, whereas the former can be used to gate 
the treatment in case of organ motion.
It will be shown, that the introduction of new technologies such as 
IGRT and 4D Radiation therapy signiﬁcantly helped reducing compli-
cations and paved the way for more aggressive treatment schedules, 
(in)directly improving outcome. It is with the clinical introduction 
of IGRT that we start to understand the true concept of margins and 
organ motion. The adoption of new technologies in IGRT, not only 
allowed for more precise and aggressive therapies, but also inﬂuenced 
the indications of radiation therapy and initiated a revision of gener-
ally accepted fractionation schemes and concepts of radiobiology. New 
imaging modalities help avoiding inter-observer variation, and provide 
increased functional/biological information of the tumour to focus the 
treatment more efﬁciently. These developments will guide us to “paint 
dose by numbers” acknowledging the heterogeneous nature of tumours 
so far neglected by delivering homogeneous dose distributions. Finally, 
this review will demonstrate the necessity of a close collaboration and 
synergy between the different disciplines in combating cancer.
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Background: Particle beams have a distinct physical advantage over 
conventional photon beams. Particle beams have a low entrance dose, a 
maximal dose at any prescribed depth, called the “Bragg peak”, and no 
exit dose. The “Bragg peak” can be spread out and shaped to conform 
to the depth and volume of an irregular target. Particle beam therapy 
(PBT) can thus create an inherently three-dimensional conformal dose 
distribution without extra dose to the surrounding normal tissue com-
pared with conformal photon treatment. At present, two particle beams 
are used for clinical purpose in the world. One is proton beam and 
the other is carbon-ion beam. The difference of these particle beams 
is its biological effect. Proton beam has a value of relative biological 
effectiveness (RBE) as 1.1, which would be considered to be almost 
identical biological effect with X-rays. In contrast, RBE of carbon-ion 
beam is estimated to be 3.0, and this high value is expected carbon-ion 
beam would be more effective for radio-resistant tumors. In Japan, PBT 
for lung cancer was performed under respiratory gating irradiation that 
means beam will turn on in only end expiration phase, and irradiated 
volume can be minimized. However, in western countries, respiratory 
gating system is rarely used.
Literature review: Most of the published articles employing PBT 
were focus on treating early stage no-small cell lung cancer (NSCLC), 
especially for Stage I disease. At University of Tsukuba, 51 NSCLC 
patients were treated with PBT with protons. Stage I, II, III, IV patients 
were 28, 9, 8, 5, respectively. The 5-year overall survival rate for Stage 
IA and IB were 70% and 16%, respectively (1). At Loma Linda Univer-
sity Medical Center, hypofractionated PBT with protons with 51 cobalt 
Gray equivalent (CGE) or 60 CGE in 10 fractions were delivered for 
22 and 46 Stage I NSCLC patients, respectively. With a median fol-
low-up period of 30 months, 3-year disease speciﬁc survival rates were 
72% (2). At the National Institute of Radiological Sciences in Japan, 
hypofractionated PBT with carbon-ions has been conducted (3-5). Re-
cently, results of 51 patients with Stage I NSCLC treated with 72 CGE 
in 9 fractions were reported. With a median follow-up period of 59.2 
months, 5-year cause speciﬁc survival rates were 75.7% (IA: 89.4; IB: 
55.1), and overall survival 50.0% (IA: 55.2%; IB: 42.9%). No severe 
acute and late toxicities were observed in all the published literatures.
NCC experiences: We already reported our initial experience of PBT 
with protons for Stage I NSCLC (6), and updated results were ana-
lyzed. Between December 1999 and September 2006, 77 patients with 
stage I NSCLC were treated by PBT with protons in our institution. 
The indication of PBT were 1) clinical stage I NSCLC, 2) PaO2 > 60 
torr, 3) medically inoperable, or refusal of surgery, 4) performance sta-
tus 0-2, 5) written informed consent. The target volume was deﬁned as 
the gross tumor volume (GTV) plus appropriate margins for subclinical 
tumor extension. In general, 8 mm margin was added for all directions 
as the clinical target volume (CTV). Margins for set-up error and respi-
ratory motion were added for planning target volume (PTV). Treatment 
was performed using respiratory gating with strain gauge. Based on 
the analysis of respiratory movement during gating irradiation, 5 mm 
internal margin for respiratory movement was added. A total dose of 
70 - 94 CGE was delivered in 20 fractions over 4 to 5 weeks. Kaplan-
Meier method and CTC-AE version 3.0 were used to assess survival 
and toxicity. 
Patients characteristics were as follows: median age 75 years (range, 52 
to 87); male/female, 54/23; Stage IA/IB, 43/34; squamous/ adeno-
carcinoma/ others, 28/23/26; total dose 70/80/88/94 CGE, 3/57/16/1. 
The initial response rate was 74% (95% conﬁdence interval (CI), 63 
to 83%). With a median follow-up period of 24 months (range, 3 to 82 
months), the 2-year local progression-free and overall survivals were 
94% (95%CI, 87 to 99%) and 91% (95% CI, 83 to 99%)(Fig.1), respec-
tively. No severe acute toxicity was observed. Late grade 2 and grade 
3 pulmonary toxicities were observed in 5 and 3 patients, respectively. 
Four patients experienced fractures of ribs within irradiated volume. 
The 2-year loco-regional progression-free survivals in stage IA and 
IB patients were 95% (95% CI, 88 to 100%) and 67% (95% CI, 50 to 
84%)(Fig. 2), respectively. Six of 8 patients who suffered late grade 2 
or greater pulmonary toxicities had stage IB disease. 
Conclusions: Literature review and updated our data show that PBT 
with both protons and carbon-ions is a promising treatment modal-
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ity for stage I NSCLC. Luck of evidence of PBT for locally advanced 
NSCLC is disappointing (several facilities are conducting clinical 
trials), the greatest opportunity for improved outcome in patients with 
locally advanced NSCLC is ﬁrmly believed the combination of PBT 
with higher doses that possible with photons today, and concurrent 
chemotherapy.
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Since CT screening for lung cancer began in 1993 in the context of the 
Early Lung Cancer Action Project (ELCAP) (1, 2), it has expanded 
into an international collaboration called I-ELCAP (3) with over 
35,000 people have undergone baseline and annual repeat screening 
following the I-ELCAP regimen of screening. At baseline, it was been 
found that 15% had a positive result of the initial CT test and at annual 
repeat screening, 6% had a positive result (4). The updated deﬁnition 
of a positive result of the initial CT test at baseline (5) is an updated 
version of that originally used in original ELCAP: at least 1 solid or 
part-solid noncalciﬁed nodule 5 mm or more in diameter, and/or at 
least 1 nonsolid noncalciﬁed nodule 8 mm or more in diameter. When 
noncalciﬁed nodules were identiﬁed but all of them were too small to 
imply a positive result, the result was viewed as ‘semi-positive’ in the 
sense of calling for repeat CT one year later. For repeat screening, the 
deﬁnition of positive result of the initial CT test remained the same as 
the original ELCAP: any newly identiﬁed noncalciﬁed nodule that evi-
dently had grown since the prior screen, regardless of size or anything 
else, except that deﬁnition of growth was updated to account for nodule 
consistency: alternatives to any enlargement, identiﬁed visually by the 
radiologist, of the entire nodule included growth of the solid compo-
nent of a part-solid nodule and development of a solid component in a 
previously nonsolid nodule.
The I-ELCAP regimen provides recommendations for the work-up, but 
the actual decision is left to each screenee and his/her referring physi-
cian. In the I-ELCAP approach, this does not compromise the validity 
of the study as long as actions, results of the subsequent tests, and inter-
ventions are documented for each screenee. Adherence to the regimen, 
however, does affect the performance of the regimen as it determines 
the frequency of unnecessary biopsy or surgery and the timeliness of 
the diagnosis which ultimately determines the stage and resectability of 
the screen-diagnosed lung cancer. Thus, for adequate performance of 
any screening regimen, adherence to it by the screenees and their refer-
ring physicians is important. 
Following the I-ELCAP protocol, over 90% of the recommended 
biopsies resulted in a diagnosis of malignancy (4). Thus, the recom-
mendations turned out to be quite successful as to avoidance of undue 
invasive procedures, complications, and cost. None of the biopsies 
performed without the regimen’s recommendation resulted in diagnosis 
of lung cancer. Detailed pathologic review of the specimens showed all 
were genuine lung cancers and showed the differences between cancers 
diagnosed in the baseline round from those diagnosed in the repeat 
rounds (6).
These screenings have resulted in 85% of the screen-diagnoses as being 
of clinical Stage I diagnosis (4). We also found a signiﬁcant decrease in 
the frequency of Stage I with increasing tumor diameter (7). The per-
centages of Stage I cases were much higher than those reported from 
the SEER registry data, although the trend was evident in the SEER 
data as well (8). Long-term follow-up of early diagnoses in the SEER 
was also addressed (9, 10). 
